8-Dec-2025
Prognostic tool could help clinicians identify high-risk cancer patients
Massachusetts Institute of TechnologyPeer-Reviewed Publication
A new decision framework developed by MIT researchers shows that, when patients with aggressive T-cell lymphoma relapse within 12 months of initial therapy, their chances for survival decline dramatically. This prognostic marker could help clinicians identify high-risk patients earlier.
- Funder
- Daiichi Sankyo, Secure Bio, Inc., Acrotech Biopharma, Kyowa Hakko Kirin, Center for Lymphoma Research, National Cancer Institute, Massachusetts General Hospital, Reid Fund for Lymphoma Research, American Cancer Society, Scarlet Foundation